Pacira price target lowered to $58 from $67 at RBC Capital

RBC Capital analyst Randall Stanicky lowered the firm’s price target on Pacira to $58 from $67 but keeps an Outperform rating on the shares. The company’s guidance cut for Exparel sales brings caution in the near-term, but also grounds RBC’s still-intact Exparel out-year performance expectations made possible by its conservative views going into the print, the analyst tells investors in a research note.